ClinicalTrials.gg
RecruitingNCT07392645Updated Oct 26, 2026

Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms

An interventional study of Electroacupuncture (EA) and Sham Electroacupuncture (SEA) in Generalized Anxiety Disorder, sponsored by Lishu Gao. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Lishu Gao · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 21, 2026Now RecruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Generalized Anxiety Disorder with a site in China — 17 open to participants now, 17 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.

Planned enrollment
10th of 21
123 · median 120
Started
2026
with 8 others
No phase
12 of 24
10 open now
Primary completion
2027-10
later than 13 of 16 live
Registered
17th of 24
by date
Lead sponsor
1 of 24
Lishu Gao

Among the 24 studies in Generalized Anxiety Disorder with a site in China, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 9 that started in 2026, is one of 12 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 17th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

17 of the 24 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Generalized Anxiety Disorder with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) as an adjunctive treatment for generalized anxiety disorder (GAD). Participants in the clinical trial will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group. All participants in the clinical trial will receive monotherapy with one of three SSRIs: sertraline, paroxetine, or escitalopram, selected by a psychiatrist according to clinical suitability, previous treatment response, and tolerability. Clinical efficacy will be assessed using the Hamilton Anxiety Rating Scale (HAMA). The neuroimaging substudy will include healthy controls and two groups of patients with GAD receiving SSRI monotherapy with an unchanged medication type and daily dose for at least 2 weeks: an EA group and a sham EA group. Healthy controls will undergo a single resting-state functional MRI (rs-fMRI) scan, whereas patients will undergo scans before and after a single 30-minute EA or sham EA session on the same day. Functional connectivity (FC), regional homogeneity (ReHo), and amplitude of low-frequency fluctuation (ALFF) will be compared between healthy controls and patients before intervention, and pre-to-post changes will be compared between the EA and sham EA groups.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Electroacupuncture
  • Generalized Anxiety Disorder
  • fMRI
  • Clinical Efficacy
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for Generalized Anxiety Disorder (GAD).
  • the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment.
  • HAMA score ≥ 14.
  • Right-handed(for MRI).
  • Aged 18-60 years, with at least primary school education.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Complicated with severe cardiovascular, cerebrovascular, or organic diseases.
  • History of other psychiatric disorders (e.g., schizophrenia, bipolar disorder).
  • for MRI (e.g., metal implants, claustrophobia).
  • Pregnancy or lactation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture (EA) Group

    Participants will receive electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.

    Procedure: Electroacupuncture (EA) · Drug: Medication

  • Sham comparator
    Sham Electroacupuncture (SEA) Group

    Participants will receive sham electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.

    Procedure: Sham Electroacupuncture (SEA) · Drug: Medication

  • Active comparator
    Waiting-list (WL) Group

    Participants will receive SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist, and will be offered delayed electroacupuncture according to the study protocol.

    Drug: Medication

Interventions

  • ProcedureElectroacupuncture (EA)

    Electroacupuncture (EA) is performed at acupoints including GV20 (Baihui), EX-HN1 (Sishencong), GV29 (Shenting), EX-HN16 (Anmian, bilateral), HT7 (Shenmen, bilateral), PC6 (Neiguan, bilateral), CV6 (Qihai), CV4 (Guanyuan), ST36 (Zusanli, bilateral), SP6 (Sanyinjiao, bilateral), and LR3 (Taichong, bilateral). Sterile disposable needles (φ0.18×25mm or φ0.25×40mm) are used. Electric stimulation (continuous wave, 100Hz) is applied to specific point pairs (e.g., left Sishencong + anterior Sishencong) for 30 minutes. The current intensity is adjusted to the patient's maximum tolerance. Treatment is administered 3 times per week for 4 weeks (12 sessions total).

  • ProcedureSham Electroacupuncture (SEA)

    Sham electroacupuncture (SEA) is performed by inserting needles into non-acupoints located 5-10 mm away from the real points used in the EA group. Shallow needling (depth of 1-2 mm) is applied. A sham EA device with a disconnected electrode lead is used; although the screen displays parameters identical to the EA group, there is no actual current output. The duration, frequency, and total number of sessions are identical to the EA group (3 times/week for 4 weeks).

  • Each participant will receive only one of the following SSRIs: sertraline, paroxetine, or escitalopram. Medication selection will be made by a psychiatrist before randomization. Dosing and dose adjustments will follow the prespecified medication management protocol, with the same rules applied across all three study groups. Any medication changes and their reasons will be recorded.

06

What researchers measure

Primary outcomes

  1. Effective rate of HAMA score reduction at Week 4

    The percentage of participants who achieved a HAMA score reduction rate of ≥50% from baseline. HAMA scores are evaluated to categorize outcomes as recovered, markedly effective, effective, or ineffective.

    Time frame: Week 4 (at the end of treatment)

Secondary outcomes

  1. Change from Baseline in Hamilton Anxiety Scale (HAMA) Scores

    HAMA is used to assess the severity of anxiety symptoms. It contains 14 items, including somatic and psychic anxiety. Total scores range from 0 to 56, where higher scores indicate more severe anxiety

    Time frame: Baseline, Week 2, Week 4, and Week 8

  2. Change from Baseline in Zung Self-Rating Anxiety Scale (SAS) Scores

    The SAS is a 20-item self-report scale assessing anxiety symptoms. Each item is scored from 1 to 4, with positively worded items reverse-scored. The total raw score ranges from 20 to 80 and is multiplied by 1.25 to obtain a standardized score ranging from 25 to 100. Higher scores indicate more severe anxiety. Changes from baseline will be assessed at Weeks 2, 4, and 8, with negative changes indicating improvement.

    Time frame: Baseline, Week 2, Week 4, and Week 8.

  3. Change from Baseline in Social Disability Screening Schedule (SDSS) Scores

    SDSS is used to evaluate the daily functioning of patients. It consists of 10 items, with each item scored from 0 to 2. Higher total scores reflect a higher degree of social disability.

    Time frame: Baseline, Week 2, Week 4, and Week 8

  4. Frequency of Participants with Changes in medication Dosage

    The study will record whether the daily dose of medication increased, remained unchanged, or decreased compared to the baseline.

    Time frame: Week 2, Week 4, and Week 8

Other outcomes

  1. Changes in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)

    Resting-state fMRI will assess FC, ReHo, and ALFF in healthy controls during a single scan and in patients with GAD before and after a single 30-minute EA or sham EA session. Pre-intervention measures in patients will be compared with those in healthy controls, and pre-to-post changes will be compared between the EA and sham EA groups.

    Time frame: Patients: before and after a single 30-minute EA or sham EA session, on the same day. Healthy controls: a single assessment.

  2. Adverse Events

    Adverse events such as bleeding, haematoma, or unbearable pain caused by the needle, as well as drug-induced nausea, vomiting or dizziness, will all be recorded.

    Time frame: Up to week 8

  3. Acupuncture Treatment Adherence

    At the end of the 4-week intervention, treatment adherence will be assessed in the electroacupuncture and sham electroacupuncture groups. The adherence rate will be calculated for each participant as the number of treatment sessions attended divided by the total number of scheduled sessions (12), multiplied by 100%. Higher percentages indicate better adherence.

    Time frame: Week 4 (at the end of treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 19 months is below that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 6, 2026
StartActual
Mar 10, 2026was Feb 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added — first site in China
Show site
  • Affiliated Hangzhou First People's Hospital · Hangzhou, China
Oct 21, 2026
Start date
Feb 1, 2026→Mar 10, 2026 (actual)
Oct 21, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore No antidepressant or anti-anxiety medication in the past 2 weeks.Now the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment.
Oct 21, 2026
Interventions
Changed Routine Medication→Medication
Oct 21, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 21, 2026
  • EditedFrequency of Participants with Changes in Paroxetinemedication DosageTime frame: Week 2, Week 4, and Week 8
  • AddedChange from Baseline in Zung Self-Rating Anxiety Scale (SAS) ScoresTime frame: Baseline, Week 2, Week 4, and Week 8.
  • RemovedTreatment Emergent Symptom Scale (TESS) ScoresTime frame: Week 2, Week 4, and Week 8
  • RemovedChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Time frame: Baseline and Week 4
  • RemovedChanges in Brain Metabolite Concentrations via Magnetic Resonance Spectroscopy (MRS)Time frame: Baseline and Week 4
  • Addedother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Time frame: Before and after a single EA/sham EA session or duration-matched rest period, on the same day.
  • Addedother outcomeAdverse EventsTime frame: Up to week 8
  • Addedother outcomeAcupuncture Treatment AdherenceTime frame: Week 4 (at the end of treatment)
What changed on Oct 26, 2026
  • Time frameother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Before and after a single EA/sham EA session or duration-matched rest period, on the same day. → Patients: before and after a single 30-minute EA or sham EA session, on the same day. Healthy controls: a single assessment.
  • Descriptionother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF): how it is measured was reworded
across 2 updates, Oct 21, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Before and after a single EA/sham EA session or duration-matched rest period, on the same day. → Patients: before and after a single 30-minute EA or sham EA session, on the same day. Healthy controls: a single assessment.
    • Descriptionother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF): how it is measured was reworded
    + 1 other change: description
  2. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Affiliated Hangzhou First People's Hospital · Hangzhou, China
    Start date Feb 1, 2026→Mar 10, 2026 (now actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore No antidepressant or anti-anxiety medication in the past 2 weeks.Now the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment.
    Secondary outcomes 1 edited, 4 added, 3 removed
    What changed in the outcomes
    • EditedFrequency of Participants with Changes in Paroxetinemedication DosageTime frame: Week 2, Week 4, and Week 8
    • AddedChange from Baseline in Zung Self-Rating Anxiety Scale (SAS) ScoresTime frame: Baseline, Week 2, Week 4, and Week 8.
    • RemovedTreatment Emergent Symptom Scale (TESS) ScoresTime frame: Week 2, Week 4, and Week 8
    • RemovedChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Time frame: Baseline and Week 4
    • RemovedChanges in Brain Metabolite Concentrations via Magnetic Resonance Spectroscopy (MRS)Time frame: Baseline and Week 4
    • Addedother outcomeChanges in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)Time frame: Before and after a single EA/sham EA session or duration-matched rest period, on the same day.
    • Addedother outcomeAdverse EventsTime frame: Up to week 8
    • Addedother outcomeAcupuncture Treatment AdherenceTime frame: Week 4 (at the end of treatment)
    Interventions Changed Routine Medication→Medication
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07392645
Lead sponsor
Lishu Gao
Responsible party
Lishu Gao (Associate Chief Physician, First People's Hospital of Hangzhou) — Sponsor-investigator
First posted
Feb 6, 2026
Start date
Mar 10, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Lishu Gao
Contact
rodelo@sina.com
+86 13858015836

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion